Specific Management of the Patients with Rheumatological Diseases and Limited Respiratory Tuberculosis
https://doi.org/10.58838/2075-1230-2024-102-5-22-29
Abstract
The objective: to analyze specific management of the patients with rheumatological diseases and limited respiratory tuberculosis.
Subjects and Methods. Management and treatment of 46 patients with limited respiratory tuberculosis was compared and analyzed. Of those, 22 patients (Case Group) had rheumatological diseases and 24 patients (Control Group) had no such disorders. There were no significant differences in age, gender, and dissemination of tuberculosis between the groups.
Results. Other diseases were found to be more common in Case Group – 81.8% versus 37.5% in Control Group (p<0.05). In the same group, persons with three or more concomitant diseases predominated – 36.4% versus 4.2% in Control Group (p <0.05). In Case Group, the majority of patients were managed by a rheumatologist due to rheumatoid arthritis – 14/22 people (63.6%). At the time of tuberculosis detection, all patients with rheumatological pathology were receiving immunosuppressive therapy; they continued taking it while tuberculosis was diagnosed and treated. In both observation groups, a high proportion of invasive techniques used to verify respiratory tuberculosis was noted: 45.4% and 62.5%, respectively (p>0.05). There was no statistically significant difference in incidence of drug-resistant tuberculosis between the groups (p>0.05). It was established that successful anti-tuberculosis chemotherapy was possible during treatment of rheumatoid diseases (Case Group); there were no statistically significant differences in effectiveness versus Control Group (p>0.05).
About the Authors
O. M. Gordeeva
Central Tuberculosis Research Institute
Russian Federation
Russian Federation
Olga M. Gordeeva, Candidate of Medical Sciences, Researcher of Center for Respiratory Diseases Diagnosis and Rehabilitation, Head of Consulting Department, Phthisiologist
2 Yauzskaya Alleya, Moscow, 107564 Phone: +7 (499) 785-90-01
S. G. Surkova
Central Tuberculosis Research Institute
Russian Federation
Russian Federation
Sofya G. Surkova, Junior Researcher of Center for Respiratory Diseases Diagnosis and Rehabilitation, Endoscopist, Pulmonologist
2 Yauzskaya Alleya, Moscow, 107564 Phone: +7 (499) 785-90-01
I. Yu. Shabalina
Central Tuberculosis Research Institute
Russian Federation
Russian Federation
Irina Yu. Shabalina, Candidate of Medical Sciences, Senior Researcher of Center for Respiratory Diseases Diagnosis and Rehabilitation, Endoscopist
2 Yauzskaya Alleya, Moscow, 107564 Phone: +7 (499) 785-90-01
N. L. Karpina
Central Tuberculosis Research Institute
Russian Federation
Russian Federation
Nataliya L. Karpina, Doctor of Medical Sciences, Deputy Director for Research, Head of Center for Respiratory Diseases Diagnosis and Rehabilitation, Phthisiologist, Pulmonologist
2 Yauzskaya Alleya, Moscow, 107564 Phone: +7 (499) 785-90-01
References
1. Barkanova O.N., Gagarina S.G., Kaluzhenina A.A. Steroid tuberculosis. Colloquium Journal, 2020, vol. 57, no. 5, pp. 52-54. (In Russ.)
2. Belov B.S., Gridneva G.I., Aronova E.S., Nasonov E.L. Chronic and opportunistic infections in patients with immuno-inflammatory rheumatic diseases: screening and prevention issues (based on the materials of the EULAR recommendations). Nauchno-Prakticheskaya Revmatologiya, 2023, vol. 61, no. 1, pp. 16-24. (In Russ.)
3. Borisov S.E., Lukina G.V., Slogotskaya L.V., Guntupova L.D., Kulikovskaya N.V. Screening and monitoring of tuberculous infection in rheumatologic patients, treated by genetically engineered biological agents. Tuberculosis and Lung Diseases, 2011, no. 6, pp. 42-50. (In Russ.)
4. Klinicheskie rekomendatsii Tuberkulez u vzroslykh. [Guidelines on tuberculosis in adults].Approved by Russian MoH, 2022. Available: https://tub-spb.ru/wp-content/uploads/2022/06/klinicheskie-rekomendaczii-tuberkulez-uvzroslyh-utv.-minzdravom-rossii.pdf?ysclid Accessed September 25, 2024
5. Metodicheskie Rekomendatsii po skriningu i monitoringu tuberkuleznoy infektsii u bolnykh, poluchayuschikh genno-inzhenernye biologicheskie preparaty. [Guidelines for screening and monitoring of tuberculous infection in rheumatologic patients, treated by genetically engineered biological agents]. 2018. Available: https://rekomendaciiborisovtuberkulez.doc (live.com) Accessed August 01, 2024.
6. Nasonov E.L., Aleksandrova E.N., Novikov A.A. Autoimmune rheumatic diseases – problems of immunopathology and personalized treatment. Vestnik RAMN, 2015, vol. 70, no. 2, pp. 169-182. (In Russ.) https://doi.org/10.15690/vramn.v70i2.1310
7. Skrining i monitoring tuberkuleznoy infektsii u revmatologicheskikh bolnykh, poluchayuschikh genno-inzhenernye biologicheskie preparaty. Metodicheskie rekomendatsii. [Screening and monitoring of tuberculous infection in patients, treated by genetically engineered biological agents. Guidelines]. Moscow Government Department of Health, Moscow Research and Clinical Center for Tuberculosis Control, compiled by Borisov S.E., Moscow, 2018, 32 p., 21. ISBN 978-5-6043340-7-2
8. Agarwal S., Das S.K., Agarwal G.G., Srivastava R. Steroids decrease prevalence of positive tuberculin skin test in rheumatoid arthritis Implications on anti-TNF therapies. Interdiscip Perspect Infect Dis., 2014, 2014, pp. 430134. https://doi.org/10.1155/2014/430134
9. Anton C., Machado F.D., Ramirez J.M.A., Bernardi R.M., Palominos P.E., Brenol C.V., Mello F.C.Q., Silva D.R. Latent tuberculosis infection in patients with rheumatic diseases. J. Bras Pneumol., 2019, vol. 45, no. 2, pp. e20190023. https://doi.org/10.1590/1806-3713/e20190023
10. Davidson A., Gunay A., Colmegna I., Lacaille D., Loewen H., Meltzer M., Tadese Y., Yirsaw Z., Bernatsky S., Hitchon C. Safety of Low Dose Methotrexate (MTX) and Tuberculosis (TB) [abstract] Available: https://acrabstracts.org/abstract/safety-of-low-dose-methotrexate-mtx-and-tuberculosis-tb/ Accessed 01.10.24.
11. Hofland R.W., Thijsen S.F., Verhagen M.A., Schenk Y., Bossink A.W. Tuberculosis during TNF-α inhibitor therapy, despite screening. Thorax, 2013, vol. 68, no. 11, pp. 1079-1080. https://doi.org/10.1136/thoraxjnl-2012-202974
12. Keane J., Gershon S., Wise R.P. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. New Eng. J. Medicine, 2001, vol. 345, no. 15, pp. 1098-1104.
13. Liu Y.J., Xu J., Guo Q. et al. The prevalence of latent tuberculosis infection in patients with inflammatory arthritis and the diagnostic efficacy of different screening methods. Zhonghua Yi Xue Za Zhi, 2019, vol. 99, no. 1, pp. 20-24. https://doi.org/10.3760/cma.j.issn.0376-2491.2019.01.005
14. Long W., Cai F., Wang X., Zheng N., Wu R. High risk of activation of latent tuberculosis infection in rheumatic disease patients. Infect. Dis. (Lond), 2020, vol. 52, no. 2, pp. 80-86. https://doi.org/10.1080/23744235.2019.1682187
15. Nam S.H., Oh J.S., Hong S., Shim T.S., Lee C.K., Yoo B. et al. Early discontinuation of tofacitinib in patients with rheumatoid arthritis co-treated with rifampin for latent tuberculosis. Joint Bone Spine, 2020, vol. 87, no. 5, pp. 475-479 https://doi.org/10.1016/j.jbspin.2020.04.010
16. McAllister W.A., Thompson P.J., Al-Habet S.M., Rogers H.J. Rifampicin reduces effectiveness and bioavailability of prednisolone. Br. Med. J. (Clin. Res. Ed.), 1983, vol. 286, no. 6369, pp. 923-925. https://doi.org/10.1136/bmj.286.6369.923
17. Tubach F., Salmon D., Ravaud P. Research Axedon Tolerance of Biotherapies Group. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French research axed on tolerance of biotherapies registry. Arthritis & Rheumatology, 2009, vol. 60, no. 7, pp. 1884-1894.
18. Vanhoof J., Landewe S., Van Wijngaerden E., Geusens P. High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors. Ann. Rheum. Dis., 2003, vol. 62, no. 12, pp. 1241-1242. https://doi.org/10.1136/ard.2002.004598
19. Van Vollenhoven R., Nishimoto N., Yamanaka H. et al. Experience with mycobacterium tuberculosis infection reported in the tocilizumab worldwide RA safety database. Ann. Rheum. Dis., 2009, vol. 68, suppl. 3, pp. 567.
20. Winthrop K.L., Park S.H., Gul A., Cardiel M.H., Gomez-Reino J.J., Tanaka Y. et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann. Rheum. Dis., 2016, vol. 75, no. 6, pp. 1133-1138. https://doi.org/10.1136/annrheumdis-2015-207319
Review
For citations:
Gordeeva O.M., Surkova S.G., Shabalina I.Yu., Karpina N.L. Specific Management of the Patients with Rheumatological Diseases and Limited Respiratory Tuberculosis. Tuberculosis and Lung Diseases. 2024;102(5):22-29. (In Russ.) https://doi.org/10.58838/2075-1230-2024-102-5-22-29
Views:
271
Email this article 